Business Context and Reporting Period
This Form 8-K was filed by Abbott Laboratories on October 21, 2016, reporting a corporate event that occurred on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing status change.
Material Changes
- Delisting: Abbott completed the cancellation of its common share listing on the London Stock Exchange.
- Continued Listings: Abbott common shares remain listed on the New York Stock Exchange, the Chicago Stock Exchange, and the SIX Swiss Exchange.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items related to financial performance.
Investor Verification Checklist
- Confirm the effective date of the London Stock Exchange delisting.
- Verify current trading availability on the NYSE, Chicago Stock Exchange, and SIX Swiss Exchange.
- Review subsequent filings for any impact on liquidity or investor access resulting from the delisting.